Filtering by:
Non-Hodgkin LymphomaFDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
A Pioneer in Developing Drugs for People with T-Cell Lymphoma
Owen A. O'Connor, MD, PhD, was awarded the prestigious American Cancer Society Clinical Research Professor grant in July 2018. He was selected because of his expertise and ongoing work to develop drugs to improve treatments for people with Hodgkin and non-Hodgkin lymphomas. He's a professor and researcher at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center in New York, New York.
FDA Approves Poteligeo (Mogamulizumab) for Lymphoma of the Skin
The US Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab) to treat people with some types of skin lymphoma.
FDA Approves Calquence (Acalabrutinib) for Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) has approved a targeted therapy for treating certain adults with mantle cell lymphoma.
FDA Approves Yescarta (Axicabtagene Ciloleucel) for Adults with Certain Lymphomas
The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) to treat adults with certain types of large B-Cell lymphoma.
Brain Tumor Survivor Puts a Positive Spin on Treatment
Howard Tolchin figured if he had to spend every other week in the hospital getting chemotherapy for a brain tumor, he was going to make the most of it.
FDA Approves Imbruvica (Ibrutinib) for Waldenstrom Macroglobulinemia
The US Food and Drug Administration has approved Imbruvica (Ibrutinib) for people with Waldenstrom Macroglobulinemia.
FDA Approves Idelalisib (Zydelig) for Leukemia and Lymphoma
The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for people with relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma (another type of non-Hodgkin lymphoma).